20 Jul March Biosciences
Sarah Hein, Ph.D., CEO
Oct. 11 | 10:45am | Rentschler ATMP Ballroom
March Biosciences, Inc, is a clinical-stage cell therapy company committed to advancing patient care in hematological malignancies by unlocking challenging targets. The lead asset, MB-105, is a CD5-targeted CAR T-cell therapy in Phase 1 studies for T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL) at Baylor College of Medicine. The unique design of MB-105 addresses key challenges in applying cell therapies to T-cell malignancies, including on-target toxicities against normal T-cells, fratricide, and terminal T-cell differentiation, without complex gene editing. MB-105 has shown promising safety and efficacy signals and is being advanced to Phase 2 studies.